mechlorethamine has been researched along with Melanoma in 55 studies
nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous NMR studies demonstrated that lonidamine (LND) selectively diminishes the intracellular pH (pHi) of DB-1 melanoma and mouse xenografts of a variety of other prevalent human cancers while decreasing their bioenergetic status (tumor βNTP/Pi ratio) and enhancing the activities of melphalan and doxorubicin in these cancer models." | 7.83 | Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. ( Garman, B; Glickson, JD; Leeper, DB; Nath, K; Nathanson, KL; Nelson, DS; Putt, ME, 2016) |
| "In the human melanoma cell line MM127 , the melphalan survival curve was linear and exhibited reciprocity with respect to concentration and treatment time." | 7.67 | Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. ( Parsons, PG, 1984) |
| "The formation and removal of nitrogen mustard (HN2)- and melphalan-induced DNA cross-links (DNA interstrand and DNA-protein cross-links) in a human melanoma cell line (RPMI 8322), as determined by alkaline elution of DNA, was compared and related to the cytotoxic effect of each drug." | 7.67 | Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. ( Hansson, J; Lewensohn, R; Nilsson, B; Ringborg, U, 1987) |
| "Forty-two patients with intransit metastases of melanoma in a limb were treated by isolated regional perfusion chemotherapy using mechlorethamine (nitrogen mustard)." | 7.67 | Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). ( Fortner, JG; Gould-Rossbach, P; Guerra, J; Horowitz, G; Knapper, WH; Ray, C; Schnog, J; Shiu, MH; Yeh, S, 1986) |
| " The additional use of mechlorethamine or oral psoralen plus UV-A, but not radiation, was significantly associated with the development of basal cell carcinoma and squamous cell carcinoma, but not malignant melanoma." | 4.79 | Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation. ( Braverman, IM; Feldman, AM; Kacinski, BM; Licata, AG; Wilson, LD, 1995) |
| "Previous NMR studies demonstrated that lonidamine (LND) selectively diminishes the intracellular pH (pHi) of DB-1 melanoma and mouse xenografts of a variety of other prevalent human cancers while decreasing their bioenergetic status (tumor βNTP/Pi ratio) and enhancing the activities of melphalan and doxorubicin in these cancer models." | 3.83 | Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. ( Garman, B; Glickson, JD; Leeper, DB; Nath, K; Nathanson, KL; Nelson, DS; Putt, ME, 2016) |
| "The cytotoxic effects of the bifunctional DNA-reactive drugs cisplatin, mustine and melphalan were studied in two human melanoma cell lines, RPMI 8322 and A 375." | 3.68 | Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin. ( Edgren, M; Fichtinger-Schepman, AM; Hansson, J; Ringborg, U, 1991) |
| "In the human melanoma cell line MM127 , the melphalan survival curve was linear and exhibited reciprocity with respect to concentration and treatment time." | 3.67 | Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. ( Parsons, PG, 1984) |
| "The formation and removal of nitrogen mustard (HN2)- and melphalan-induced DNA cross-links (DNA interstrand and DNA-protein cross-links) in a human melanoma cell line (RPMI 8322), as determined by alkaline elution of DNA, was compared and related to the cytotoxic effect of each drug." | 3.67 | Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. ( Hansson, J; Lewensohn, R; Nilsson, B; Ringborg, U, 1987) |
| "Forty-two patients with intransit metastases of melanoma in a limb were treated by isolated regional perfusion chemotherapy using mechlorethamine (nitrogen mustard)." | 3.67 | Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). ( Fortner, JG; Gould-Rossbach, P; Guerra, J; Horowitz, G; Knapper, WH; Ray, C; Schnog, J; Shiu, MH; Yeh, S, 1986) |
| "Thirteen patients with advanced (Stage III) malignant melanoma have been treated with high-dose chemotherapy (nitrogen mustard or a combination of BCNU and melphalan) combined with autologous, nonfrozen, bone marrow transplantation." | 3.66 | Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study. ( Dantas, ME; Glode, LM; Koeppler, H; Morton, N; Robinson, WA; Sutherland, J; Thomas, MR, 1982) |
| " It is the authors' conclusion that the portable isolated limb perfusion system achieved all of the required parameters to provide safe and effective treatment for this type of melanoma." | 1.29 | Safe, compact and portable system for regional chemotherapeutic hyperthermic perfusion procedures. ( Faddis, D; Fried, SJ; Miller, R; Weaver, FA, 1993) |
| " Cytostatics are dosed per liter of perfused extremity." | 1.27 | [Technic of isolated perfusion of the extremities. Experience with 171 cases]. ( Aigner, K; Schwemmle, K, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (83.64) | 18.7374 |
| 1990's | 7 (12.73) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (3.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lyons, AB | 1 |
| Mitchell, DA | 1 |
| Moy, RL | 2 |
| Nath, K | 1 |
| Nelson, DS | 1 |
| Putt, ME | 1 |
| Leeper, DB | 1 |
| Garman, B | 1 |
| Nathanson, KL | 1 |
| Glickson, JD | 1 |
| LUCK, JM | 1 |
| CREECH, O | 4 |
| RYAN, RF | 4 |
| KREMENTZ, ET | 5 |
| HOLLAND, JF | 1 |
| REGELSON, W | 2 |
| WESTBURY, G | 1 |
| HUMBLE, JG | 1 |
| NEWTON, KA | 1 |
| SKINNER, ME | 1 |
| PEGG, DE | 1 |
| IRVINE, WT | 1 |
| NOON, CF | 1 |
| MANIZADE, D | 1 |
| SALEPCIOGLU, A | 1 |
| AKTAN, K | 1 |
| ARIEL, IM | 1 |
| PACK, GT | 1 |
| KENNEDY, BJ | 1 |
| ZELICKSON, AS | 1 |
| CALCUTT, G | 1 |
| CONNORS, TA | 1 |
| BRINDLEY, CO | 1 |
| SALVIN, LG | 1 |
| POTEE, KG | 1 |
| LIPOWSKA, B | 1 |
| SHNIDER, BI | 1 |
| COLSKY, J | 1 |
| BOGUSZ, J | 1 |
| BUTELSKI, W | 1 |
| SYCH, M | 1 |
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| MAUER, AM | 1 |
| KRILL, CE | 1 |
| VIGI, F | 1 |
| SHINGLETON, WW | 1 |
| PARKER, RT | 1 |
| DOWD, JE | 1 |
| DIPAOLO, JA | 1 |
| WATNE, AL | 1 |
| FRIEDMAN, BI | 1 |
| SAENGER, EL | 1 |
| KREINDLER, MS | 1 |
| DECOSSE, JJ | 1 |
| ROGERS, LS | 1 |
| LAWRENCE, W | 1 |
| TAYAO, MS | 1 |
| MAHAJAN, RD | 1 |
| PAGE, R | 1 |
| MILLER, DG | 1 |
| CLAPP, P | 1 |
| KONDO, T | 1 |
| ICHIHASHI, H | 1 |
| BIRINGER, A | 1 |
| HOLAN, J | 1 |
| MEDLA, F | 1 |
| JONES, KO | 1 |
| REEVE, TS | 1 |
| PIPER, DW | 1 |
| CUMBERLAND, VH | 1 |
| Markman, M | 1 |
| Aigner, K | 2 |
| Schwemmle, K | 1 |
| Cosnes, A | 1 |
| Revuz, J | 1 |
| Wechsler, J | 1 |
| Touraine, R | 1 |
| Parsons, PG | 1 |
| Thomas, MR | 1 |
| Robinson, WA | 2 |
| Glode, LM | 2 |
| Dantas, ME | 1 |
| Koeppler, H | 1 |
| Morton, N | 1 |
| Sutherland, J | 1 |
| Hofer, D | 2 |
| Dubitsky, AM | 1 |
| Reïlly, P | 2 |
| Santoro, MG | 3 |
| Jaffe, BM | 3 |
| Dubitsky, A | 1 |
| Marti, J | 1 |
| Hild, P | 1 |
| Hundeiker, M | 1 |
| Hartmann, DW | 1 |
| Morton, NJ | 1 |
| Mangalik, A | 1 |
| Leport, P | 1 |
| Favalli, C | 1 |
| Rinaldi, C | 1 |
| Licata, AG | 1 |
| Wilson, LD | 1 |
| Braverman, IM | 1 |
| Feldman, AM | 1 |
| Kacinski, BM | 1 |
| Quinn, TD | 1 |
| Polk, HC | 1 |
| Edwards, MJ | 1 |
| Carter, RD | 1 |
| Sutherland, CM | 1 |
| Muchmore, JH | 1 |
| Lamb, PM | 1 |
| Menaker, GM | 1 |
| Amichai, B | 1 |
| Grunwald, MH | 1 |
| Goldstein, J | 1 |
| Finkelstein, E | 1 |
| Halevy, S | 1 |
| Fried, SJ | 1 |
| Miller, R | 1 |
| Weaver, FA | 1 |
| Faddis, D | 1 |
| Klein, E | 1 |
| Rosner, D | 1 |
| Holtermann, OA | 1 |
| Stoll, HL | 1 |
| Song, SY | 1 |
| Hansson, J | 2 |
| Fichtinger-Schepman, AM | 1 |
| Edgren, M | 1 |
| Ringborg, U | 2 |
| Lewensohn, R | 1 |
| Nilsson, B | 1 |
| Shiu, MH | 1 |
| Knapper, WH | 1 |
| Fortner, JG | 1 |
| Yeh, S | 1 |
| Horowitz, G | 1 |
| Schnog, J | 1 |
| Guerra, J | 1 |
| Gould-Rossbach, P | 1 |
| Ray, C | 1 |
| Helman, P | 1 |
| Sealy, R | 1 |
| Malherbe, E | 1 |
| Anderson, J | 1 |
| Anderson, CB | 1 |
| Philpott, GW | 1 |
| Ferguson, TB | 1 |
| Hill, GJ | 1 |
| Larsen, RR | 1 |
| Hersh, EM | 1 |
| McBride, CM | 2 |
| Gschwind, C | 1 |
| Mahaley, MS | 1 |
| Woodhall, B | 1 |
| Jelicić, I | 1 |
| Pasini, M | 1 |
| Prpić, I | 1 |
| Relja-Vladović, T | 1 |
| Hancević, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melphalan Intra-arterial Chemotherapy for Choroidal Melanoma Chemoreduction - a Phase I Clinical Trial[NCT05893654] | Phase 1/Phase 2 | 10 participants (Anticipated) | Interventional | 2021-05-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mechlorethamine and Melanoma
| Article | Year |
|---|---|
Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Electrons; Female; Humans; Lymphoma, T | 1995 |
1 trial available for mechlorethamine and Melanoma
| Article | Year |
|---|---|
Newer techniques in cancer chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bleomycin; Bone Marrow Transplantation; Carcinoma; Ce | 1984 |
53 other studies available for mechlorethamine and Melanoma
| Article | Year |
|---|---|
Topical chemotherapy for numerous superficial basal cell carcinomas years after isolated limb perfusion for melanoma.
Topics: Administration, Cutaneous; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents | 2019 |
Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell S | 2016 |
The action of the phenylalanine mustards and of several homologs on mouse melanoma.
Topics: Animals; Mechlorethamine; Melanoma; Melphalan; Neoplasms, Experimental; Nitrogen Mustard Compounds | 1957 |
Treatment of melanoma by isolation-perfusion technique.
Topics: Humans; Leg; Mechlorethamine; Melanoma; Neoplasms; Nitrogen Mustard Compounds; Perfusion; Phenylalan | 1959 |
Studies of phenylalanine nitrogen mustard (CB 3025) in metastatic malignant melanoma of man.
Topics: Humans; Mechlorethamine; Melanoma; Nitrogen Mustard Compounds; Phenylalanine | 1958 |
A CLINICAL study of the comparative effect of nitrogen mustard and DON in patients with bronchogenic carcinoma, Hodgkin's disease, lymphosarcoma, and melanoma.
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Hodgkin Disease; Humans; Leucine; Lymphoma; Lymphoma | 1959 |
Disseminated malignant melanoma: response to treatment by massive dosage of a cytotoxic agent combined with autogenous marrow replacement.
Topics: Antineoplastic Agents; Bone Marrow; Cytotoxins; Mannitol; Mechlorethamine; Melanoma; Nitrogen Mustar | 1959 |
The treatment of malignant melanoma by perfusion techniques.
Topics: Humans; Mechlorethamine; Melanoma; Nitrogen Mustard Compounds; Perfusion | 1961 |
[A case of malignant melanoma of the leg treated by isolated perfusion of nitrogen mustard].
Topics: Extracorporeal Circulation; Humans; Leg; Mechlorethamine; Melanoma; Nitrogen Mustard Compounds; Perf | 1960 |
Treatment of disseminated melanoma with phenylalanine mustard (melphelan) and autogenous bone marrow transplants.
Topics: Bone Marrow; Bone Marrow Transplantation; Humans; Mechlorethamine; Melanoma; Melphalan; Nitrogen Mus | 1962 |
Chemotherapy of melanoma of the extremities by isolated perfusion.
Topics: Antineoplastic Agents; Extremities; Mechlorethamine; Melanoma; Neoplasms; Nitrogen Mustard Compounds | 1962 |
MELANOMA IN AN ALBINO.
Topics: Albinism; Electrons; Mechlorethamine; Melanins; Melanoma; Microscopy; Microscopy, Electron; Neoplasm | 1963 |
TUMOUR SULPHYDRYL LEVELS AND SENSITIVITY TO THE NITROGEN MUSTARD MEROPHAN.
Topics: Animals; Lymphoma; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mechlorethamine; Mela | 1963 |
FURTHER COMPARATIVE TRIAL OF TRIETHYLENE THIOPHOSPHORAMIDE AND MECHLORETHAMINE IN PATIENTS WITH MELANOMA AND HODGKIN'S DISEASE.
Topics: District of Columbia; Hodgkin Disease; Mechlorethamine; Melanoma; New York; Thiotepa; Toxicology | 1964 |
[RESULTS IN THE CHEMOTHERAPY OF MALIGNANT NEOPLASMS USING THE APPARATUS FOR EXTRACORPOREAL CIRCULATION].
Topics: Chemotherapy, Cancer, Regional Perfusion; Extracorporeal Circulation; Heart, Artificial; Humans; Leg | 1963 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
A STUDY OF THE MECHANISMS OF GRANULOCYTOPENIA.
Topics: Agranulocytosis; Anemia; Anemia, Macrocytic; Carcinoma; Carcinoma, Bronchogenic; Child; Hodgkin Dise | 1964 |
[ANTINEOPLASTIC PREPARATIONS USED AS A MEANS OF PROTECTION AGAINST THE FREE ELEMENTS IN THE BLOOD AND CONTAMINATION BY NEOPLASTIC CELLS, IN OPERATIVE INTERVENTIONS].
Topics: Antineoplastic Agents; Carcinoma; Cyclophosphamide; Hodgkin Disease; Humans; Mechlorethamine; Melano | 1963 |
REGIONAL PERFUSION IN MELANOMA OF LIMBS.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Extremities; Humans; Mechlorethamin | 1964 |
ABDOMINAL PERFUSION FOR CANCER CHEMOTHERAPY USING HYPOTHERMIA AND HYPERTHERMIA.
Topics: Abdomen; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Cycloph | 1964 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
ENDOREDUPLICATION IN LEUCOCYTE CHROMOSOMES. PRELIMINARY REPORT OF ITS RELATION TO CANCER AND WHOLE-BODY IRRADIATION.
Topics: Breast Neoplasms; Chromosome Aberrations; Chromosome Disorders; Chromosomes; Cobalt Isotopes; Coloni | 1964 |
EFFECT OF HYPERBARIC OXYGEN AND CANCER CHEMOTHERAPY ON GROWTH OF ANIMAL TUMORS.
Topics: Animals; Cricetinae; Humans; Hyperbaric Oxygenation; Injections, Intraperitoneal; Lung Neoplasms; Me | 1964 |
SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY.
Topics: Biomedical Research; Carcinoma; Carcinoma, Squamous Cell; Dogs; Geriatrics; Infusions, Parenteral; I | 1964 |
[INDUCTION OF METASTASES BY TREATMENT WITH CARCINOSTATIC AGENTS. II. DEPRESSION OF HOST RESISTANCE AND ANTIBODY PRODUCTION].
Topics: Animals; Anti-Bacterial Agents; Antibody Formation; Cattle; Chemotherapy, Cancer, Regional Perfusion | 1964 |
OUR EXPERIENCES WITH CYTOSTATIC PERFUSIONS OF THE EXTREMITIES IN THE TREATMENT OF MALIGNANT TUMORS.
Topics: Animals; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Dogs; Drug Ther | 1964 |
Disseminated abdominal melanoma treated by massive dosage of nitrogen mustard and autogenous bone-marrow replacement.
Topics: Bone Marrow; Bone Marrow Transplantation; Humans; Mechlorethamine; Medical Records; Melanoma; Nitrog | 1960 |
[Technic of isolated perfusion of the extremities. Experience with 171 cases].
Topics: Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Drug Therapy, Combination; Ex | 1983 |
[Melanoma and dysplastic nevus after 8 years of topical Caryolysine].
Topics: Administration, Topical; Female; Humans; Mechlorethamine; Melanoma; Middle Aged; Nevus, Pigmented; P | 1984 |
Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines.
Topics: Caffeine; Cell Line; Cell Survival; Chlorambucil; DNA, Neoplasm; Drug Resistance; Drug Synergism; Ho | 1984 |
Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; | 1982 |
The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Cell Count; Cell Division; Doxorubicin; Female; Fluorouraci | 1980 |
Prostaglandin E augments the effect of chemotherapy on B-16 melanoma in vivo.
Topics: Animals; Antineoplastic Agents; Dopamine; Doxorubicin; Drug Therapy, Combination; Female; Fluorourac | 1982 |
[New modifications in isolated extremity perfusion ].
Topics: Antineoplastic Agents; Arm; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Dacarbazine; Dactin | 1982 |
High-dose nitrogen mustard (HN2) with autologous nonfrozen bone marrow transplantation in advanced malignant melanoma. A phase I trial.
Topics: Adolescent; Bone Marrow Transplantation; Drug Evaluation; Female; Humans; Hypocalcemia; Male; Mechlo | 1981 |
PGE restores the immune response in chemotherapy-treated, tumor-bearing mice.
Topics: 16,16-Dimethylprostaglandin E2; Animals; Antibody Formation; Doxorubicin; Drug Therapy, Combination; | 1982 |
Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Combined M | 1995 |
Regional chemotherapy for melanoma. A 35-year experience.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Clinical Trials as Topic; Combined Modality T | 1994 |
Multiple basal cell carcinomas of the limb after adjuvant treatment of melanoma with isolated limb perfusion.
Topics: Antineoplastic Agents, Alkylating; Carcinoma, Basal Cell; Chemotherapy, Adjuvant; Chemotherapy, Canc | 1998 |
Small malignant melanoma in patients with mycosis fungoides.
Topics: Adult; Antineoplastic Agents, Alkylating; Humans; Male; Mechlorethamine; Melanoma; Middle Aged; Myco | 1998 |
Safe, compact and portable system for regional chemotherapeutic hyperthermic perfusion procedures.
Topics: Adult; Aged; Arm; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Dactinomycin; | 1993 |
Nonspecific antigen reactions.
Topics: Administration, Topical; Antibody Formation; Antigens; Antineoplastic Agents; BCG Vaccine; Breast Ne | 1976 |
Comparative study of two human melanoma cell lines with different sensitivities to mustine and cisplatin.
Topics: Cell Line; Cell Survival; Cisplatin; DNA, Neoplasm; Glutathione; Humans; Mechlorethamine; Melanoma; | 1991 |
Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells.
Topics: Cell Line; Cell Survival; DNA; Humans; Mathematics; Mechlorethamine; Melanoma; Melphalan; Neoplastic | 1987 |
Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard).
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Extremities; Female; Humans; Hyperthermia, In | 1986 |
Intra-arterial cytotoxic therapy and x-ray therapy for cancer of the head and neck.
Topics: Adenoma, Pleomorphic; Carcinoma, Squamous Cell; Facial Neoplasms; Fibrosarcoma; Head; Head and Neck | 1965 |
The treatment of malignant pleural effusions.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamou | 1974 |
Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience.
Topics: Adult; Aged; Arm; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Leg; Male; Mechlorethami | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Local and systemic immunologic effects of perfusion therapy for malignant melanoma.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Dactinomycin; E | 1973 |
Regional chemotherapeutic perfusion and infusion of brain and face tumors.
Topics: Adenocarcinoma; Ameloblastoma; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carcinoma; Carci | 1967 |
[Regional perfusion with nitrogen mustard in the treatment of malignant tumors of the lower extremities].
Topics: Adolescent; Adult; Angiokeratoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion | 1969 |
Advanced melanoma of the extremities.
Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Child; Dactinomycin; Female; Huma | 1970 |